2010's Top Biopharma Dealmakers
Generics, emerging markets, orphan diseases and earn-out heavy M&A were the recurring dealmaking themes in 2010. We focus here on the dealmakers, showing which companies dominated the dealmaking landscape in terms of deal volume and value, as well as the therapeutic categories that grabbed the most attention.
You may also be interested in...
2010 was a year of transition, filled with the exploration of new industry models. Health care reform hinted at short-term pain and long-term gain while investment, R&D and commercial challenges combined with a heightened sense of industry desperation to bring out biopharma's creative side. But as with any experiment, there is ample risk of failure.
American Injectables plans to build up its US-based manufacturing after securing a commitment for $10m of ‘Series A’ financing from New Rhein Healthcare Investors, which it will use to scale up production and launch several generic parenteral products.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.